We are 2′-DEOXYGUANOSINE CAS:312693-72-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Molecular Formula:C10H13N5O4
Molecular Weight:267.24100
Physical and Chemical Properties:
Melting point:300ºC
Boiling point:801.4ºC
Flash point:438.5ºC
Appearance:White to off-white crystalline powder
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:2’-Deoxyguanosine Monohydrate is a nucleoside analog.


Related News: Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.D-Norleucine CAS:327-56-0 The Company’s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.dichloromethyl(triethoxy)silane CAS:19369-03-0 DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation.142404-69-1 Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.

Related Products
Product Name
Vindoline Cas:2182-14-1 View Details
Cesium Nitrate Cas:7789-18-6 View Details
2-Amino-3-picoline View Details
(2-Butyl-5-nitrobenzofuran-3-yl)(4-methoxyphenyl)methanone Cas:141627-42-1 manufacturer 3,4-ethylenedioxythiophene Cas:126213-50-1 manufacturer Diethyltoluenediamine (DETDA) Cas:68479-98-1 manufacturer 5-Bromo-2-Carboxy-3-Methylpyridine manufacturer 2-Hydroxy-4-methoxybenzaldehyde manufacturer